MCP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement
PARSIPPANY, NJ JUNE 29, 2010
MCP Pharmaceuticals, a leading provider of contract manufacturing services for sterile injectables, vaccines, ophthalmics and otics announced today that it has entered into a multi-year contract supply agreement with an undisclosed ophthalmic company. Under terms of the agreement, MCP will be responsible for manufacturing and supply of a proprietary ophthalmic product, which is targeted for launch next year.
Stuart Hinchen co-founder and president of MCP stated, “We are very pleased that MCP was chosen for this large-scale multi-year contract. Our knowledgeable staff, approach to technology transfer and cGMP compliance record with the FDA, EMEA and ANVISA allows us to serve this important customer. We have a long history of successful partnerships, manufacturing both commercial products and products in development with experience taking products from clinical trial supplies to commercial manufacturing.”
About MCP Pharmaceuticals, LLC
MCP Pharmaceuticals, headquartered in New Jersey, provides contract manufacturing of sterile injectable products for large and small pharmaceutical and biotech organizations. MCP’s sterile manufacturing facility, located in Rochester Michigan sits on over 80 acres of land and includes a 171,000 sq. ft. production building and 44,000 sq. ft. warehouse. The production facility utilizes five high-speed filling lines and seven lyophilizers.
The site also includes separate facilities for chemistry, sterility testing, and analytical methods development. MCP has the capability to manufacture small-scale clinical or large-scale commercial products. MCP employs more than 330 staff in the USA in its manufacturing, sales & marketing and corporate areas. For more information, please visit jhppharma.com
Additional Press Releases
 |
MCP Pharmaceuticals Enters Agreement To Produce Life-Saving Drug Webpage | PDF Format |
|
MCP Pharmaceuticals Announces Chief Executive Officer Succession Webpage | PDF Format |
|
MCP Pharmaceuticals Launches New Multipack Presentations of Adrenalin®, Coly-Mycin® M and Pitocin® Webpage | PDF Format |
|
MCP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement Webpage | PDF Format |
|
MCP Pharmaceuticals Enters Another Multi-Year Contract Manufacturing Agreement Webpage | PDF Format |
|
|
MCP Pharmaceuticals & Putney Inc. Announce Multi-Year Contract Manufacturing Agreement Webpage | PDF Format |
|
MCP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement Webpage | PDF Format |
|
MCP Pharmaceuticals Announces Successful Completion of FDA and EMEA GMP Audits Webpage | PDF Format |
|
MCP Announces FDA Approval for Dantrium IV, rapidly mixing in 20 seconds Webpage | PDF Format |
|
MCP Pharmaceuticals & SpePharm complete purchase of Dantrium® (dantrolene sodium) Webpage | PDF Format |
|
King Pharmaceuticals Completes Sale Of Rochester, Michigan Manufacturing Facility To MCP Pharmaceuticals Webpage | PDF Format |
Return To Press & News »
